2011 Reaxys PhD Prize opens for entries

Global competition for PhD students of chemistry

Elsevier Properties has launched the 2011 Reaxys PhD Prize, a global competition for candidates currently studying for a PhD or having completed a PhD within the last 12 months.

The prize will be awarded for original and innovative research in organic, organometallic and inorganic chemistry to the candidates that demonstrate excellence in methodology and approach.

Three prizewinners will each receive US$2,000 and will be invited to present their research at the Winners’ Symposium during the 14th Asian Chemical Congress, which takes place from 5–8 September in Bangkok, Thailand.

David Evans, scientific affairs director at Elsevier Properties, said: ‘The Reaxys PhD Prize celebrates innovation and creativity in chemistry research from around the world, values which lie at the heart Reaxys itself.’

He continued: ‘In 2010 we received more than 300 submissions from around the world covering the breadth of modern chemistry. The quality of research was outstanding, and the finalists and winners are clearly at the cutting edge of chemistry research. A high bar has been set for 2011.’

All entries will be evaluated by a review board of leading international chemists, chaired by the Professor A G M Barrett, Imperial College London, UK; Professor B M Trost, Stanford University, US; and Professor H N C Wong, Chinese University of Hong Kong, China, who are members of the Reaxys Advisory Board.

All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by 28 February to the Reaxys PhD Prize website.

Elsevier Properties SA a division of scientific publisher Reed Elsevier that manages intellectual property. It owns the PharmaPendium, Beilstein and Reaxys databases.

You may also like

Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part II)

Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations
Manufacturing

Kindeva to showcase complex drug delivery expertise at CPHI 2025

Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities
Research & Development

AI-powered Viro3D becomes world’s largest database of human and animal virus proteins

Scientists at the MRC-University of Glasgow Centre for Virus Research have launched a free database containing structural models for 85,000 proteins from 4400 viruses, paving the way for faster development of vaccines and antiviral drugs
Subscribe now